Latest News

Latest News

News from the World Hepatitis Alliance

The World Hepatitis Alliance and UNITE partner to combat viral hepatitis

26 Sep 2019 Lucy Ferrier

LONDON, UNITED KINGDOM (September 26, 2019) The World Hepatitis Alliance (WHA) and UNITE, the global parliamentarians network to end HIV/AIDS, viral...

Universal Health Coverage: what it means for viral hepatitis

25 Sep 2019 Lucy Ferrier

- written by Cary James, World Hepatitis Alliance CEO On Monday 23rd September I attended the United Nations (UN) High Level Meeting on Universal...

WHA and UNITE host side meeting at the United Nations High-Level Meeting on UHC

19 Sep 2019 Chris Wingrove

Securing political leadership and innovative funding to achieve Universal Health Coverage. Where: UNAIDS New York office, 801 2nd Avenue/43rd St....

United Against Hepatitis- A Network for Hepatitis Free Society

12 Sep 2019 Isabel Bull

In 2016, 194 governments including that of India committed to eliminating viral hepatitis as a public health threat by 2030. In doing so, India has committed to diagnosing 30 per cent of people living with viral hepatitis by 2020 and 90 per cent of people by 2030....

World Hepatitis Alliance and IAPAC Announce Fast-Track Cities Partnership

9 Sep 2019 Lucy Ferrier

The World Hepatitis Alliance (WHA) and the International Association of Providers of AIDS Care (IAPAC) announced a new partnership today on the first day of the Fast-Track Cities 2019 conference in London....

hepinion: Exploring a pioneering catalytic funding mechanism for elimination in Uzbekistan

3 Sep 2019 Tash Priya

In Uzbekistan around 5,300 people die each year from liver disease and cancer related to hepatitis B or C. The tragedy is that almost all of these deaths are preventable. Uzbekistan, like many other low- to middle-income countries, faces a huge economic and social burden because of viral hepatitis. With no global funder present to help them to tackle the disease, new innovative models of financing need to be explored to make hepatitis elimination a reality....

PRIME® launch Practical Toolkit for Building a Successful Partnership with High-Risk Hepatitis C Patients.

29 Aug 2019 Lucy Ferrier

Leading healthcare education and research company PRIME® has launched a practical toolkit aimed at aligning patients and providers in the prevention and treatment of hepatitis C....

World Hepatitis Day special: hepVoice August is Out Now

27 Aug 2019 Lucy Ferrier

The August 2019 edition of hepVoice, the monthly e-magazine from the World Hepatitis Alliance....

hepinion: We must invest in viral hepatitis

30 Jul 2019 Chris Wingrove

Earlier this year JHEP released an article entitled ‘Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017’. Encouragingly, the article concludes that countries are making progress with respect to national hepatitis planning. However, there remains a major issue: financing....

hepVoice July is Out Now

25 Jul 2019 Lucy Ferrier

The July 2019 edition of hepVoice, the monthly e-magazine from the World Hepatitis Alliance...

Presidents message ahead of World Hepatitis Day

25 Jul 2019 Chris Wingrove

World Hepatitis Day is the one day when the world unites to celebrate the progress made towards the elimination of viral hepatitis. Progress that has...

hepinion: stigma and discrimination affects everyone

10 Jul 2019 Lucy Ferrier

On April 21, 2019, the shocking news came out that Pakistani cricketer Shadab Khan had been ruled out of the series against England prior to the Cricket World Cup 2019 after being diagnosed with hepatitis C. Shadab is a key player of Pakistan, the only specialist spinner in the 15 player squad. It’s really unfortunate for someone just diagnosed with hepatitis C to be withdrawn from their duties, and entirely unnecessary. If a renowned player like Shadab Khan became a victim of discrimination than what about common people?...

hepVoice June is Out Now

26 Jun 2019 Lucy Ferrier

The June 2019 edition of hepVoice, the monthly e-magazine from the World Hepatitis Alliance...

WORLD HEPATITIS ALLIANCE SUPPORTS EFFORTS TO INCREASE THE DIAGNOSIS OF VIRAL HEPATITIS

20 Jun 2019 Chris Wingrove

A new digital tool released today (20 June) will support advocacy efforts to find the 290 million people who are unaware that they are living with...

hepinion: The evidence is in, governments need to recognise the value of civil society

29 May 2019 Lucy Ferrier

Cary James, CEO of World Hepatitis Alliance (WHA), explores the importance and impact of civil society engagement in the creation and implementation of hepatitis elimination strategies...

hepVoice May is Out Now

29 May 2019 Lucy Ferrier

The May 2019 edition of hepVoice, the monthly e-magazine from the World Hepatitis Alliance...

hepinion: Patients have an important role to play in the development of a hepatitis B cure

2 May 2019 Lucy Ferrier

In April the International Coalition to Eliminate Hepatitis B (ICE-HBV) launched the ‘Global Scientific Strategy to Cure hepatitis B’, setting out a roadmap for the global scientific community to discover a cure for hepatitis B. In this opinion piece, WHA President-elect Dr Su Wang discusses the important role patients have to play in the development of a hepatitis B cure....

hepVoice April is Out Now

30 Apr 2019 Lucy Ferrier

The April 2019 edition of hepVoice, the monthly e-magazine from the World Hepatitis Alliance...

Vacancy: Project Coordinator

25 Apr 2019 Bridie Taylor

The World Hepatitis Alliance is currently recruiting for a Project Coordinator to assist with the ongoing delivery of World Hepatitis Alliance...

Find And The World Hepatitis Alliance Team Up To Amplify Advocacy For Hepatitis C Diagnosis

16 Apr 2019 Lucy Ferrier

• FIND and the World Hepatitis Alliance (WHA) join forces to co-ordinate and strengthen advocacy and communications efforts for hepatitis C diagnostics through joint initiatives nationally, regionally and globally • Memorandum of Understanding signed on the sidelines of the 2019 EASL International Liver Congress™...

Pages

News from infohep

Public-sector hepatitis C treatment programmes expanding in lower- and middle-income countries

8 Jan 2021 Keith Alcorn
Public-sector hepatitis C treatment programmes have cured tens of thousands of people in lower- and lower-middle-income countries with the aid of low...

Semaglutide alone or in combination regimens shows promise for NASH

18 Dec 2020 Liz Highleyman
Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without...

Lanifibranor improves NASH in 24-week trial

18 Dec 2020 Keith Alcorn
Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b...

Efruxifermin improves liver fat and fibrosis in people with NASH

15 Dec 2020 Keith Alcorn
Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial...

High hepatitis C cure rate achieved in New York prisons

9 Dec 2020 Keith Alcorn
Hepatitis C treatment in prisons can result in a high cure rate but people released from prison during treatment are less likely to be cured due to...

2.5 million people in Africa need urgent hepatitis B treatment

9 Dec 2020 Keith Alcorn
Around 2.5 million people with hepatitis B in sub-Saharan Africa already have cirrhosis and need immediate antiviral treatment, a systematic review...

Few countries will meet 2020 target for reducing viral hepatitis deaths

24 Nov 2020 Keith Alcorn
Around 1.1 million deaths were caused by viral hepatitis worldwide in 2019 and deaths due to hepatitis C are still rising despite the availability of...

Some hepatitis B patients can safely stop antivirals

24 Nov 2020 Liz Highleyman
Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead...

Can investment in hepatitis C treatment be cost saving?

24 Nov 2020 Keith Alcorn
Direct-acting antiviral treatment for hepatitis C can be cost saving for some countries within five to ten years, especially if they can negotiate...

Tenofovir alafenamide prevents mother-to-child hepatitis B virus transmission

20 Nov 2020 Liz Highleyman
Tenofovir alafenamide (TAF; Vemlidy) is highly effective at preventing transmission of hepatitis B virus (HBV) from mothers with a high viral load to...